Randomised Open-Label Multicenter Prosp. Clinical Study to Show the Efficacy of IV ZOMETA 4mg for Prevention of Bone Metastases in Hormone-naive High Risk Patients With Locally Advanced Prostate Cancer.
Phase of Trial: Phase III
Latest Information Update: 30 Apr 2012
At a glance
- Drugs Zoledronic acid (Primary)
- Indications Bone metastases; Prostate cancer
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 05 Jun 2009 New trial record.